Evidence map›Paper›PMID 39075604›Full record

ReviewMolecular brain2024

β-hydroxybutyrate and ischemic stroke: roles and mechanisms.

Ge Feng, Zongkai Wu, Leyi Yang, Kaimeng Wang, Hebo Wang

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Molecular brain, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Ge FengGraduate School of Hebei Medical University, Shijiazhuang, Hebei, China.
Zongkai WuDepartment of Neurology, Hebei General Hospital, No. 348 21 Heping West Road, Shijiazhuang, 050051, Hebei, China.
Leyi YangGraduate School of Hebei Medical University, Shijiazhuang, Hebei, China.
Kaimeng WangGraduate School of Hebei Medical University, Shijiazhuang, Hebei, China.
Hebo WangDepartment of Neurology, Hebei General Hospital, No. 348 21 Heping West Road, Shijiazhuang, 050051, Hebei, China. wanghbhope@hebmu.edu.cn.ORCID 0000-0002-0598-5772

Funding

Central Government Guided Local Science and Technology Development Fund Project 236Z7745GNatural Science Foundation of Hebei Province H2020307041
6 · The paper itself

Abstract

Stroke is a significant global burden, causing extensive morbidity and mortality. In metabolic states where glucose is limited, ketone bodies, predominantly β-hydroxybutyrate (BHB), act as alternative fuel sources. Elevated levels of BHB have been found in the ischemic hemispheres of animal models of stroke, supporting its role in the pathophysiology of cerebral ischemia. Clinically, higher serum and urinary BHB concentrations have been associated with adverse outcomes in ischemic stroke, highlighting its potential utility as a prognostic biomarker. In both animal and cellular models, exogenous BHB administration has exhibited neuroprotective effects, reduction of infarct size, and improvement of neurological outcomes. In this review, we focus on the role of BHB before and after ischemic stroke, with an emphasis on the therapeutic potential and mechanisms of ketone administration after ischemic stroke.

Indexed as

3-Hydroxybutyric AcidIschemic StrokeAnimalsBrain IschemiaHumans3-Hydroxybutyric AcidIschemic strokeNeuroprotective effectPrognostic biomarkerβ-hydroxybutyrate

Identifiers

PMID39075604
PMCPMC11287974

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.